---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-197065"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:39:38.784020+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Inovio Q2 net loss $32.2M; INO-3107 BLA submission delayed to mid-2025 due to device manufacturing issue

## Summary
- Net loss of $32.2M ($1.19/share) vs $35.5M ($1.61/share) in Q2 2023; revenue not disclosed.
- Cash, equivalents and short-term investments $110.4M; cash runway estimated into Q3 2025.
- BLA submission for lead candidate INO-3107 (RRP) delayed to mid-2025 due to manufacturing issue with disposable device component.
- Appointed Steve Egge as Chief Commercial Officer; submitted Phase 3 trial design for INO-3112 to European regulators.
- Raised $33.2M net in April 2024 stock/warrant offering.

## SEC filing metadata
- accession: 0001193125-24-197065
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312524197065/0001193125-24-197065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312524197065/d681488d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-197065
- JSON: https://secwatch.observer/filing/0001193125-24-197065.json
- Plain text: https://secwatch.observer/filing/0001193125-24-197065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.